Pluto Bio operates an enterprise-grade, AI-powered platform that gives scientists a secure, collaborative environment to explore large, high-dimensional biological datasets, run auto-scaling bioinformatics pipelines, and produce publication-ready visualizations without writing code. The platform supports a wide range of assays, including genomics, transcriptomics, epigenetics, and proteomics, and is used for target discovery, mechanism-of-action studies, translational medicine, and biomarkers/precision medicine research. Pluto integrates with existing R&D workflows, addresses data governance needs for regulated environments, and is trusted by mid-market and enterprise clients across North America and Europe. The company emphasizes putting LLMs and AI tools into the hands of domain experts to increase scientific rigor, reproducibility, and speed of insight. Pluto plans to use new capital to develop AI agents and copilots, expand integrations with other R&D tools, build out commercial roles, and accelerate deployment across therapeutic areas and modalities. The company announced a $3.6M funding round to accelerate growth and scale adoption among global pharma customers. Pluto Biosciences offers a visually elegant life sciences SaaS platform that combines data management, computational biology algorithms, and interactive visualization in a no-code canvas. Launched in 2021 from the Wyss Institute at Harvard University and headquartered in Denver, CO, Pluto serves life sciences organizations across the US and UK, from academia to public biopharma. The platform supports assays such as RNA-seq, ChIP-seq, CUT&RUN, CRISPR screens, metabolomics, proteomics, biochemical assays, and animal behavioral studies, and integrates with sequencing services, electronic lab notebooks, project management, and collaboration tools. Pluto emphasizes a biology-focused user experience to simplify bioinformatics analyses and secure data sharing so researchers can focus on discovery. The company will use the $3.7M seed investment to expand product development and go-to-market teams, develop advanced features, and increase sales velocity. Rani Powers, PhD, is CEO and Founder. Pluto Biosciences offers the Pluto collaborative life sciences platform, a cloud-based lab space that centralizes project management, experimental data (raw and processed), and interactive bioinformatics analyses accessible from a browser or via API. The product supports numerous assay types (qPCR, ELISA, imaging, RNA‑seq, metabolomics, proteomics, animal behavioral studies, and more) and provides customizable experiment pages, publication-ready plots, real-time notifications, and fine-grained role-based access controls. Paid subscriptions include unlimited user and guest collaborator seats and access to Pluto’s Scientific Solutions team for custom bioinformatics and professional services, removing the need for customers to maintain their own infrastructure. Since its launch in August, the company has doubled its staff and added discovery-enhancing features to accelerate research workflows. Pluto also launched a free Explore tier that makes more than 10,000 published experiments available to anyone with a free account. The company intends to expand bioinformatics and machine-learning–based analyses, democratize access to published research data, and close gaps in scientific collaboration.

Total raised

$8M

Funding rounds

3

Latest round

Equity

Latest activity

May 2025